Xencor公司宣布,其针对Xmab819在晚期透明细胞肾细胞癌患者中开展的一期临床研究,已被选为2026年欧洲肿瘤内科学会大会的优选论文,并将进行口头报告。
Xencor公司宣布,其针对Xmab819在晚期透明细胞肾细胞癌患者中开展的一期临床研究,已被选为2026年欧洲肿瘤内科学会大会的优选论文,并将进行口头报告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.